According to Steve Forbes, chairman and editor-in-chief of Forbes Media, “Your brand is the single most important investment you can make in your business.” As we go to press, several eye care-related companies have announced efforts to rebrand:

• VSP Global. The vision benefits company rebranded as VSP Vision and launched a new visual brand identity to “mark a new era for the purpose-driven organization,” says a press release. VSP Vision says it serves more than 85 million members and 41,000 in-network doctors. See https://vspvision.com
• Luneau Technology. This ophthalmic device company recently changed its name to Visionix and adopted a new visual identity. In addition, Optovue transitioned to a product brand for Visionix’s OCT and OCTA line. According to Luneau Technology, the rebrand also allows Visionix to improve its visibility and awareness worldwide and includes a new logo, which it says evokes upward movement to convey innovation, inspiration and speed, and appears in orange and blue to convey the company’s service to the medical field. See https://luneautechusa.com/visionix .
• Ocuco. This optical software company, which provides management systems for labs, independent practices, and chains, announced a rebrand to reflect the company’s move from providing solely single-solution applications to also providing omnichannel native systems. For example, this year the company will launch Acuitas 3 OmniChannel Edition, which will provide an omnichannel platform that has both in-store and consumer-facing facilities, says Ocuco CEO Leo Mac Canna. See https://ocuco.com .
• Alimera Sciences, Inc. The global pharmaceutical company focused on retinal health “refreshed” its brand to “better represent its current business focus and identity – approachable, energetic, and collaborative.” Specifically, its new logo includes two lowercase “A’s” that form an eye to symbolize the company joining forces with retina specialists and partners to provide patient solutions. Also, the design is comprised of a dark blue with teal accent to reflect Alimera’s main product, fluocinolone acetonide intravitreal implant 0.19 mg (ILUVIEN). Finally, the updated company tagline, “We see more, together” embodies Alimera’s mission to continue to make a positive impact on the standard of care for retina patients globally, the company says. See https://alimerasciences.com . OM